Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.
about
Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolveNovel delivery strategies for glioblastomaNimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivoNimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.The emerging role of nimotuzumab in the treatment of non-small cell lung cancer.Immunotherapy of brain cancers: the past, the present, and future directions.Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair.Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticlesStudying a complex tumor: potential and pitfalls.Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumabNimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.A Phase II Clinical Trial of Concurrent Helical Tomotherapy plus Cetuximab Followed by Adjuvant Chemotherapy with Cisplatin and Docetaxel for Locally Advanced Nasopharyngeal Carcinoma.A view on EGFR-targeted therapies from the oncogene-addiction perspective.EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical EffectsTherapeutic approaches to target cancer stem cells.Therapeutic targeting of EGFR in malignant gliomas.Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.Targeting cancer stem cells for treatment of glioblastoma multiforme.Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities.Cancer biomarker discovery: current status and future perspectives.Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.Cancer stem cells: progress and challenges in lung cancer.Featured article: autophagic activation with nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma.Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancerRadioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr.The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.The role of cancer stem cells (CD133(+)) in malignant gliomas.Clinically relevant radioresistant cell line: a simple model to understand cancer radioresistance.The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation.Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells.
P2860
Q26764947-C9AEADAC-5A50-4EA3-AA1C-F4B9D3074A98Q27006099-AF12A410-7DF2-4A2D-AF61-19395963A0ADQ27853322-477F0BBD-7FF7-4149-95DD-8913A0024CFEQ33631435-ACB531E2-03F0-4167-B90D-C6473D92B673Q34343043-FB391769-414E-4E8E-95FD-7D4CA28E1123Q34701587-ED2F76FB-BFF0-4DE9-BF7C-5B2D359DC1CEQ34778047-9B9E972E-AF7A-45FD-94AA-1118DF6BC92AQ34848038-D2B8E99B-BECA-442B-B9BC-8E51C98C7EA4Q34970294-59401B5B-40A2-4DC6-BA39-9D72ABD5205DQ35623965-75B15D01-E9CF-4FF8-B0E5-6A8253D2ADA6Q35832224-B3A2552A-C3AC-4DE2-914B-57D854AA4245Q35929525-CFC2832D-4CF2-4A77-B1C1-A8CDBFD331A5Q35955366-1116334D-3FC2-4194-B94B-9FDC80ECAAA6Q36285551-A788FF0B-3B4D-47D8-AFB6-8D132327E791Q36517741-F12E1CED-958B-4697-91A1-417843377D68Q36727111-E3012B02-5D1A-426C-B2ED-D9D779FB03ADQ36795486-FFF5648F-6ED2-433D-9CAA-132EAF575FE1Q37132708-D3980D23-6DF7-4E73-948E-380E190C39D9Q37137412-6BA736CD-ADDE-4E1B-9602-1476B74E0184Q37690755-0345913A-2CCD-482C-A072-75C1F62D5FAEQ37736273-87D140E7-5568-40B2-B7A0-797C25DA2854Q38099729-D83D604E-5998-4AF3-9D71-7C296E7C3F1FQ38127413-17E32831-2F99-42FD-9BA5-FE9B007711CDQ38187679-788E76A6-463B-4660-B831-E4389FCCD415Q38873993-3F422735-B820-4212-BE98-A13C46031F5AQ38881450-E5D1D78A-C440-4278-9DB5-82E4CF7CBE44Q39015925-E1A7CCD0-9C78-4DEB-8C2E-519562FCC223Q39139857-4EAA4B86-08BD-4D67-8B19-7ED0CBBB0D86Q39352683-4E3B49A1-371E-418A-B6EC-FA2B004BCCD0Q39385922-1F115EC0-8068-4BC8-88EC-179A23DBC418Q39410923-387B09EF-03B0-410A-BDAB-C69858360F8FQ45863982-3F82403F-3838-455C-ABDA-7FFD7551E31BQ48132579-152D4E8C-1813-4EDB-9FE4-AC5E3C7383E0Q48222651-319FD19E-793C-46B9-8147-64185CEB2629Q51060657-E2616D02-A045-41F2-B1A3-E980EE1F7B2C
P2860
Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Radiosensitisation of U87MG br ...... eceptor monoclonal antibodies.
@en
Radiosensitisation of U87MG br ...... eceptor monoclonal antibodies.
@nl
type
label
Radiosensitisation of U87MG br ...... eceptor monoclonal antibodies.
@en
Radiosensitisation of U87MG br ...... eceptor monoclonal antibodies.
@nl
prefLabel
Radiosensitisation of U87MG br ...... eceptor monoclonal antibodies.
@en
Radiosensitisation of U87MG br ...... eceptor monoclonal antibodies.
@nl
P2093
P2860
P356
P1476
Radiosensitisation of U87MG br ...... eceptor monoclonal antibodies.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604943
P407
P577
2009-03-01T00:00:00Z
P5875
P6179
1009911008